JYNT vs XPOF vs SKIN

For growth investors, The Joint Corp.

(JYNT) is the stronger pick with 5. 2% revenue growth year-over-year, versus -10. 0% for The Beauty Health Company (SKIN). The Joint Corp. (JYNT) offers the better valuation at 45. 7x trailing P/E (45. 0x forward), making it the more compelling value choice. Analysts rate The Joint Corp. (JYNT) a "Buy" — based on 8 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, Xponential Fitness, Inc.

is actually cheaper at 9. 4x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Xponential Fitness, Inc.

(XPOF) delivered a total return of -54. 3%, compared to -95. 3% for The Beauty Health Company (SKIN). Over 10 years, the gap is even starker: JYNT returned +192. 6% versus SKIN's -94. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), The Joint Corp.

(JYNT) is the lower-risk stock at 0. 94β versus Xponential Fitness, Inc. 's 1. 79β — meaning XPOF is approximately 91% more volatile than JYNT relative to the S&P 500. On balance sheet safety, The Joint Corp. (JYNT) carries a lower debt/equity ratio of 13% versus 6% for The Beauty Health Company — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), The Joint Corp.

(JYNT) is pulling ahead at 5. 2% versus -10. 0% for The Beauty Health Company (SKIN). On earnings-per-share growth, the picture is similar: The Joint Corp. grew EPS 148. 7% year-over-year, compared to 35. 2% for Xponential Fitness, Inc.. Over a 3-year CAGR, XPOF leads at 9. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

The Joint Corp.

(JYNT) is the more profitable company, earning 5. 3% net margin versus -10. 7% for Xponential Fitness, Inc. — meaning it keeps 5. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: XPOF leads at 25. 3% versus -6. 9% for SKIN. At the gross margin level — before operating expenses — JYNT leads at 79. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Xponential Fitness, Inc.

(XPOF) trades at 9. 4x forward P/E versus 45. 0x for The Joint Corp. — 35. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for JYNT: 130. 1% to $20. 00.

In this comparison, XPOF (2.

9% yield) pays a dividend. JYNT, SKIN do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, The Joint Corp.

(JYNT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 94), +192. 6% 10Y return). The Beauty Health Company (SKIN) carries a higher beta of 1. 71 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (JYNT: +192. 6%, SKIN: -94. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (JYNT (Healthcare) and XPOF (Consumer Cyclical) and SKIN (Consumer Defensive)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

XPOF pays a dividend while JYNT, SKIN do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.